Drug intelligence / Profile preview

Meratrim

Development stage
Unknown
Lead developer
InterHealth Nutraceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Meratrim (IHBG-10) is a proprietary nutraceutical combination consisting of extracts from the flower heads of *Sphaeranthus indicus* (East Indian globe thistle) and the fruit rind of *Garcinia mangostana* (Mangosteen), typically in a 3:1 ratio. Developed by InterHealth Nutraceuticals (now a part of Lonza), it is primarily used as a dietary supplement for weight management and the reduction of body fat. Meratrim exerts its effects by modulating the biological pathways involved in adipogenesis and lipolysis. Specifically, it has been shown to inhibit the differentiation of pre-adipocytes into mature fat cells and reduce lipid accumulation by downregulating key adipogenic transcription factors and proteins, such as PPAR-gamma and perilipin, while also increasing the expression of adiponectin. Beyond general weight loss, IHBG-10 was investigated in clinical trials for its potential to counteract weight gain associated with the use of atypical antipsychotic medications, although these specific applications were not advanced following pilot studies.

Brand names
Meratrim
Other names
Sphaeranthus indicus and Garcinia mangostana blendSphaeranthus indicus and Garcinia mangostana extract
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)AdipoR (Adiponectin receptor)FASN (Fatty acid synthase)

Beyond the preview

Go deeper on Meratrim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meratrim.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call